Table 1. Characteristics of included studies in this meta-analysis.
No. | First author (Year) | Country | Ethnicity | Study design | Sample size | Methylation detection method | Materials | Source of controls | Involved clinicopathological features | Quality scores | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control | CC | HSIL | LSIL | ||||||||||
1 | Nakashima 1999 [20] | Japan | Asian | Case-only | - | 33 | - | - | MSRE | Tissue | - | Tumor type | 12 |
2 | Wong 1999 [11] | China | Asian | Case-only | - | 98 | - | - | MSP | Tissue | - | FIGO stage, tumor grade, type | 10 |
3 | Dong 2001 [21] | Korea | Asian | Case-control | 24 | 53 | - | - | MSP and sequencing | Tissue | B | Tumor grade, type, early age | 15 |
4 | Virmani 2001 [22] | USA | Caucasian | Case-control | 22 | 19 | 17 | 37 | MSP | Tissue | H | - | 13 |
5 | Tsuda 2003 [15] | Japan | Asian | Case-only | - | 53 | 33 | 9 | MSP | Tissue | B | HPV infection | 13 |
6 | Gustafson 2004 [16] | USA | Caucasian | Case-control | 11 | - | 17 | 11 | Nested MSP | Tissue | H | - | 11 |
7 | Lea 2004 [23] | USA | Caucasian | Case-control | 78 | 60 | 30 | - | MSP | Tissue | H | FIGO stage, tumor grade, type, smoking, HPV infection | 14 |
8 | Yang tissue 2004 [19] | China | Asian | Case-control | 100 | 85 | - | - | MSP and sequencing | Tissue | A | FIGO stage, tumor grade, type | 13 |
9 | Yang plasma 2004 [19] | China | Asian | Case-control | 30 | 40 | - | - | MSP and sequencing | Plasma | H | - | 13 |
10 | Feng 2005 [17] | Senegal | African | Case-control | 142 | 92 | 46 | 39 | MSP | Tissue | M | - | 10 |
11 | Kim 2005 [24] | Korea | Asian | Case-control | 11 | 41 | 19 | 11 | MSP | Tissue | B | - | 11 |
12 | Lin 2005 [25] | Korea | Asian | Case-control | 20 | 47 | 10 | 20 | MSP | Tissue | B | Tumor type | 11 |
13 | Jeong 2006 [26] | Korea | Asian | Case-control | 24 | 78 | - | - | MSP | Tissue | B | FIGO stage, tumor type, early age, smoking | 15 |
14 | Kang 2006 [27] | Korea | Asian | Case-control | 5 | 43 | 7 | 31 | MSP and pyrosequencing | Tissue | B | - | 13 |
15 | Kekeeva 2006 [28] | Russia | Caucasian | Case-control | 35 | - | 42 | - | MSP | Tissue | H | - | 10 |
16 | Yang 2006 [29] | China | Asian | Case-only | - | 127 | - | - | MSP and sequencing | Tissue | - | FIGO stage, tumor grade, type | 12 |
17 | Ivanova 2006 [30] | Russia | Caucasian | Case-control | 14 | 26 | - | - | MSP and BSP | Tissue | A | - | 11 |
18 | Nehls 2008 [18] | Germany | Caucasian | Case-only | - | 70 | 16 | 8 | Nested BSM-PCR | Tissue | - | HPV infection | 12 |
19 | Attaleb 2009 [31] | Morocco | African | Case-control | 20 | 22 | - | - | MSP | Tissue | H | FIGO stage, tumor grade, HPV infection, early age | 12 |
20 | Furtado 2010 [32] | Brazil | Brazilian | Case-control | 20 | - | 27 | - | MSP | Tissue | H | HPV infection | 11 |
21 | Kim 2010 [33] | Korea | Asian | Case-control | 41 | 69 | 67 | 32 | Nested MSP | Tissue | B | - | 13 |
22 | Huang 2011 [34] | China | Asian | Case-control | 15 | 26 | 49 | 23 | MSP | Tissue | H | - | 12 |
23 | Lof-Ohlin 2011 [12] | Sweden | Caucasian | Case-only | - | 109 | - | - | Pyrosequencing | Tissue | - | - | 11 |
24 | Spathis 2011 [35] | Greece | Caucasian | Case-control | 41 | 12 | 85 | 121 | MSP | Tissue | H | Tumor type | 12 |
25 | Jha 2012 [36] | India | Asian | Case-control | 100 | 125 | - | - | MSP | Tissue | M | Smoking | 12 |
26 | Carestiato 2013 [13] | Brazil | Brazilian | Cross-sectional | 28 | 29 | 49 | 35 | MSP | Tissue | H | - | 10 |
27 | Banzai 2014 [37] | Japan | Asian | Case-control | 24 | 53 | 22 | - | MSP | Tissue | H | Tumor type | 10 |
28 | Blanco-Luquin 2015 [38] | Spain | Caucasian | Case-control | 13 | 67 | 85 | 10 | MSP | Tissue | H | Tumor type | 15 |
29 | Silveria 2015 [39] | Brazil | Brazilian | Cohort | - | 40 | - | - | MSP | Tissue | - | HPV infection | 14 |
Abbreviation: CC, cervical cancer; LSIL, low-grade squamous intra-epithelial lesion; HSIL, high-grade squamous intra-epithelial lesion; MSRE, methylation-sensitive restriction endonucleases; MSP, methylation-specific PCR; BSP, bisculfite sequencing PCR; H, healthy controls; B, controls with benign gynecological diseases; A, autologous controls; M, mixed controls.